Proteasome inhibitor

In a Wave of Innovation Coming Out of China, One Nanjing Biotech Firm Stands Out at the 2019 ASCO and EHA Annual Meetings

Retrieved on: 
Thursday, June 20, 2019
Biotechnology, Pharmaceutical, Oncology, Health, General Health, Clinical trials, Branches of biology, Orphan drugs, Drugs, Medicine, Multiple myeloma, RTT, Tocilizumab, Proteasome inhibitor, Proteasome

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    These notable meetings feature the efforts of the brightest minds driving innovation in hematology and cancer research from around the globe.
  • For newly treated patients with multiple myeloma, the common first-line treatment drugs include proteasome inhibitors, immunoregulatory drugs and alkane agents.
  • Mostly grade 1 and 2, at the low and medium dosage levels, CRS was routinely managed with Tocilizumab and steroids.
  • Among them, 40% of patients are diagnosed with moderate or high-risk multiple myeloma, and their median survival is less than five years.

Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at 2019 ASCO and EHA Annual Meetings

Retrieved on: 
Tuesday, June 18, 2019
Drugs, Medicine, Clinical medicine, Orphan drugs, Multiple myeloma, RTT, Proteasome inhibitor, Monoclonal antibodies, Cancer treatments, Smouldering myeloma, Bortezomib

CT103A is an anti-BCMA CAR-T co-developed by Innovent and IASO BIO for the treatment of Relapsed/Refractory Multiple Myeloma (RRMM).

Key Points: 
  • CT103A is an anti-BCMA CAR-T co-developed by Innovent and IASO BIO for the treatment of Relapsed/Refractory Multiple Myeloma (RRMM).
  • Multiple myeloma is a malignant hematologic cancer with abnormal proliferation of clonal plasma cells, which has no medical cure so far.
  • Among them, 40 percent of patients are diagnosed with moderate or high-risk multiple myeloma, and their median survival is less than five years.
  • For newly treated patients with multiple myeloma, the common first-line treatment drugs include proteasome inhibitors, immunoregulatory drugs and alkane agents.

Bristol-Myers Squibb Presents Updated Efficacy Data from Phase 2 Trial of Empliciti (elotuzumab) Plus Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Retrieved on: 
Friday, June 14, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Drugs, Medicine, Orphan drugs, Chemical compounds, Immunosuppressants, Aromatic amines, Breakthrough therapy, Pomalidomide, Elotuzumab, Multiple myeloma, Lenalidomide, Proteasome inhibitor

Bristol-Myers Squibb Company (NYSE: BMY) today announced the presentation of updated data from ELOQUENT-3, the international randomized Phase 2 study evaluating Empliciti (elotuzumab) plus pomalidomide and dexamethasone (EPd) versus pomalidomide and dexamethasone (Pd) alone in patients with relapsed or refractory multiple myeloma (RRMM).

Key Points: 
  • Bristol-Myers Squibb Company (NYSE: BMY) today announced the presentation of updated data from ELOQUENT-3, the international randomized Phase 2 study evaluating Empliciti (elotuzumab) plus pomalidomide and dexamethasone (EPd) versus pomalidomide and dexamethasone (Pd) alone in patients with relapsed or refractory multiple myeloma (RRMM).
  • The extended follow-up results from ELOQUENT-3 reinforce the EPd combinations sustained efficacy and favorable safety profile in patients with relapsed or refractory multiple myeloma, said Fouad Namouni, M.D., head, Oncology Development, Bristol-Myers Squibb.
  • Bristol-Myers Squibb and AbbVie are co-developing Empliciti, with Bristol-Myers Squibb solely responsible for commercial activities.
  • The Phase 2 ELOQUENT-3 trial randomized 117 patients with RRMM who received two or more prior therapies and were either refractory or relapsed and refractory to lenalidomide and a proteasome inhibitor.